Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly paclitaxel plus dual HER2-targeted neoadjuvant therapy in HER2-positive breast cancer (real-world, single-arm study vs WSG-ADAPT HER2+)
ChiCTR2100054127Phase 2Not yet recruiting
- Sponsor
- Maoming People's Hospital
- Start
- Dec 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paclitaxel, trastuzumab and pertuzumab in breast cancer, sponsored by Maoming People's Hospital. Primary endpoint: Pathological complete response rate (pCR). Planned start Dec 2021; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100054127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100054127.